Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
DentsplyXRAY |
$16M |
 |
Align TechnologyALGN |
-$13M |
 |
Silk Road MedicalSILK |
-$231M |
 |
iRhythm TechnologiesIRTC |
-$168M |
 |
LeMaitre VascularLMAT |
-$4.86B |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Paravasthu Mukund | Jan 11, 2025 | Sell | 2,160 | $26.8084 | $58,000 |
| Paravasthu Mukund | Nov 2, 2024 | Sell | 44 | $16.6858 | $730 |
| Leonard Frank X | Nov 1, 2024 | Sell | 598 | $15.9377 | $9,500 |
| Paravasthu Mukund | Nov 1, 2024 | Sell | 160 | $15.8776 | $2,500 |
| Puri Michal Nath | Oct 31, 2024 | Sell | 810 | $15.7922 | $13,000 |
| Cordova Ashley | Aug 2, 2024 | Sell | 688 | $20.1416 | $14,000 |
| VERNON W ANTHONY | Jun 4, 2024 | Sell | 964 | $23.893 | $23,000 |
| Scannell Timothy J | Jun 4, 2024 | Sell | 964 | $23.8874 | $23,000 |
| LEUNG GABRIEL | Jun 4, 2024 | Sell | 964 | $23.8851 | $23,000 |
| GROENHUYSEN WILHELMUS CM | Mar 4, 2024 | Sell | 1,217 | $16.01 | $19,000 |
| Leonard Frank X | Mar 4, 2024 | Sell | 840 | $16.01 | $13,000 |
| GROENHUYSEN WILHELMUS CM | Mar 1, 2024 | Sell | 2,107 | $16.0269 | $34,000 |
| Leonard Frank X | Mar 1, 2024 | Sell | 1,679 | $16.0269 | $27,000 |
| Leonard Frank X | Feb 28, 2024 | Sell | 2,078 | $16.1428 | $34,000 |
| GROENHUYSEN WILHELMUS CM | Feb 28, 2024 | Sell | 2,303 | $16.1428 | $37,000 |
| Shah Pritesh | Nov 7, 2023 | Sell | 382 | $12.65 | $4,800 |
| Cordova Ashley | Sep 1, 2023 | Sell | 883 | $21.8172 | $19,000 |
| GROENHUYSEN WILHELMUS CM | Sep 1, 2023 | Sell | 294 | $21.8172 | $6,400 |
| Shah Pritesh | Sep 1, 2023 | Sell | 273 | $21.8172 | $6,000 |
| Cordova Ashley | Aug 2, 2023 | Sell | 1,144 | $30.2511 | $35,000 |
| Leonard Frank X | Mar 7, 2023 | Sell | 6,003 | $74.9968 | $450,000 |
| Leonard Frank X | Mar 7, 2023 | Sell | 2,315 | $75.5937 | $170,000 |
| Shah Pritesh | Mar 3, 2023 | Sell | 16,909 | $76.1594 | $1.3M |
| GROENHUYSEN WILHELMUS CM | Mar 3, 2023 | Sell | 20,415 | $76.1594 | $1.6M |
| Leonard Frank X | Mar 3, 2023 | Sell | 4,403 | $76.1594 | $340,000 |
| Shah Pritesh | Mar 3, 2023 | Sell | 2,942 | $76.1594 | $220,000 |
| Shah Pritesh | Mar 3, 2023 | Sell | 1,570 | $76.1594 | $120,000 |
| GROENHUYSEN WILHELMUS CM | Mar 3, 2023 | Sell | 3,528 | $76.1594 | $270,000 |
| GROENHUYSEN WILHELMUS CM | Mar 3, 2023 | Sell | 1,692 | $76.1594 | $130,000 |
| Cordova Ashley | Mar 3, 2023 | Sell | 4,730 | $76.1594 | $360,000 |
| Leonard Frank X | Mar 3, 2023 | Sell | 2,059 | $77.6391 | $160,000 |
| Leonard Frank X | Mar 3, 2023 | Sell | 888 | $76.1594 | $68,000 |
| Cordova Ashley | Mar 3, 2023 | Sell | 775 | $76.1594 | $59,000 |
| Burke William Patrick | Mar 3, 2023 | Sell | 593 | $76.1594 | $45,000 |
| GROENHUYSEN WILHELMUS CM | Mar 2, 2023 | Sell | 1,213 | $75.2779 | $91,000 |
| Cordova Ashley | Mar 2, 2023 | Sell | 1,055 | $75.2779 | $79,000 |
| Leonard Frank X | Mar 2, 2023 | Sell | 3,799 | $75.3235 | $290,000 |
| Burke William Patrick | Mar 2, 2023 | Sell | 281 | $75.2779 | $21,000 |
| Shah Pritesh | Mar 2, 2023 | Sell | 937 | $75.2779 | $71,000 |
| Leonard Frank X | Mar 2, 2023 | Sell | 844 | $75.2779 | $64,000 |
| Leonard Frank X | Mar 2, 2023 | Sell | 308 | $76.0511 | $23,000 |
| Leonard Frank X | Mar 1, 2023 | Sell | 1,684 | $76.3624 | $130,000 |
| Shah Pritesh | Mar 1, 2023 | Sell | 1,923 | $76.3624 | $150,000 |
| Cordova Ashley | Mar 1, 2023 | Sell | 2,198 | $76.3624 | $170,000 |
| GROENHUYSEN WILHELMUS CM | Mar 1, 2023 | Sell | 2,164 | $76.3624 | $170,000 |
| Burke William Patrick | Mar 1, 2023 | Sell | 755 | $76.3624 | $58,000 |
What's the latest insider transaction for NovoCure?
The most recent insider transaction for NovoCure was conducted by Paravasthu Mukund, who sold 2,160 shares on January 11, 2025 at a price of $26.81 per share.
Which insider has sold the most NVCR stock over the last two years?
GROENHUYSEN WILHELMUS CM has sold the most NVCR stock in the last 2 years, with a total value of $2.3M.
What is the total value of insider transactions for NovoCure (NVCR) in the last 2 years?
The total value of insider transactions for NovoCure in the last 2 years is negative, amounting to -$6.9M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
How do insider transactions over the last 2 years reflect on NovoCure's market confidence?
Over the last 2 years, insider transactions for NovoCure have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
